{"title":"针对早期复发和/或难治性多发性骨髓瘤的BCMA导向疗法。","authors":"Niels W. C. J. van de Donk, Sonja Zweegman","doi":"10.1038/s41571-024-00927-6","DOIUrl":null,"url":null,"abstract":"BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of therapy in multiple myeloma. In addition, combination therapy with the BCMA-targeting antibody–drug conjugate belantamab mafodotin at first or subsequent relapse has the potential to improve survival of patients with this disease. This increasing number of therapeutic options makes treatment selection and sequencing increasingly complex.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BCMA-directed therapy for early relapsed and/or refractory multiple myeloma\",\"authors\":\"Niels W. C. J. van de Donk, Sonja Zweegman\",\"doi\":\"10.1038/s41571-024-00927-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of therapy in multiple myeloma. In addition, combination therapy with the BCMA-targeting antibody–drug conjugate belantamab mafodotin at first or subsequent relapse has the potential to improve survival of patients with this disease. This increasing number of therapeutic options makes treatment selection and sequencing increasingly complex.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41571-024-00927-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41571-024-00927-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of therapy in multiple myeloma. In addition, combination therapy with the BCMA-targeting antibody–drug conjugate belantamab mafodotin at first or subsequent relapse has the potential to improve survival of patients with this disease. This increasing number of therapeutic options makes treatment selection and sequencing increasingly complex.
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
